MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

MAIA Biotechnology, Inc.

Healthcare

The company does not pay dividends at all, or it pays them sporadically. There have only been a few years with dividend payments in the past ten years. 

MAIA reported revenue of USD 0mn in the last 12 months, down 0% from FY24. The dynamics of cash flow, as measure by free cash flow (FCF), were rather similar. EPS fell 27% from FY24 to USD -0.83. Market expects EPS to reach USD -1.48 in FY25.

Over the last six months, the stock performance has varied, with an increase following a drop. The stock's price trend wasn't definitive when matched against its global counterparts from the same sector and industry (as depicted above). Within the past six months, its performance has trailed this peer group's by 11ppts and its growth accelerated by 12ppts in the past month. This is equally valid for peers from the same country and industry. Given the stock's valuation versus its peers, its total price movement is neither favourable nor unfavourable.

Another important profitability metric, return on assets (RoA), amounted to -202.8% in the last 12 months, a decrease from -201.2% in FY23. The market analysts predict that RoA will be -258.7% in FY24, again weaker than its peers. 

In the last 12 months, the return on capital employed (RoCE) declined to -417.6%, below the peers. 

MAIA Biotechnology, Inc. reported a return on equity (RoE) of -727.1% in the last 12 months, down from -438.7% in FY23. The market consensus projects an RoE of -4100.2% in FY24, again behind its peers. 

The ratio of return on invested capital (RoIC) to the weighted average cost of capital (WACC) has been -95.5 in the past several years. This ratio implies a fragile shareholder value creation. 

The institutional, legal, and compliance risks associated with the company's country are minimal. In combination with stringent business standards, shareholder rights are very highly protected.

MAIA has very poor trading liquidity. The average private investor can sell his common position in the stock in a single trading day under normal market conditions. Liquidity is unstable and is average on the days with the lowest activity. The trading volume mostly stays the same even under highly turbulent market conditions. The stock has a tiny market capitalisation, which usually makes its trading liquidity erratic and unpredictable. 

No other major risks have been identified.

The risk of default is very high. Among the negative credit factors and we point to negligible return on capital, inadequate interest coverage.

In highly turbulent market conditions, MAIA is exceptionally volatile. In other words, the stock will be among the worst-performers in times of extreme market volatility or shocking company news. Standalone, the worst-day losses (less than 1% of the time) will likely be critical. 

In normal market circumstances, MAIA is exceptionally volatile. Put differently, without outstanding market volatility or shocking company news, the stock's price will change quite unpredictably. The stock's losses on its worst days (less than 1-5% of the time) will range from critical to immense. 

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. 

MAIA Biotechnology, Inc.

$ 1.82

3

MAIA Biotechnology, Inc.

$ 1.82

3

Risk factor

Profitability factor

Risk / Profitability

Risk factor

Profitability factor

$ 1.82

About

About

About

About